These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

824 related articles for article (PubMed ID: 31509426)

  • 1. Prognostic Value of the Volumetric Parameters of Dual-Time-Point
    Okazaki E; Seura H; Hasegawa Y; Okamura T; Fukuda H
    AJR Am J Roentgenol; 2019 Dec; 213(6):1366-1373. PubMed ID: 31509426
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
    Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
    Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of circulating tumor cells and 18F-FDG PET/CT for precision diagnosis in patients with non-small cell lung cancer.
    Sun M; Lu D; Li X; Wang J; Zhang L; Yang P; Yang Y; Shen J
    Cancer Med; 2024 Sep; 13(18):e70216. PubMed ID: 39302034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
    Satoh Y; Onishi H; Nambu A; Araki T
    Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of volumetric metabolic parameter changes determined by during and after radiotherapy-based
    Chen HHW; Su WC; Guo HR; Lee BF; Chiu NT
    Kaohsiung J Med Sci; 2019 Mar; 35(3):151-159. PubMed ID: 30887722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
    Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Investigation of the Relationship Between
    Kandemir O; Demir F
    Curr Radiopharm; 2024; 17(1):111-116. PubMed ID: 37644744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different Prognostic Values of Dual-Time-Point FDG PET/CT Imaging Features According to Treatment Modality in Patients with Non-Small Cell Lung Cancer.
    Jang SJ; Lee JW; Lee JH; Jo IY; Lee SM
    Tomography; 2022 Apr; 8(2):1066-1078. PubMed ID: 35448721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
    Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of prognostic values of primary tumor and nodal
    Lim CH; Hyun SH; Moon SH; Cho YS; Choi JY; Lee KH
    Eur Radiol; 2019 Oct; 29(10):5288-5297. PubMed ID: 30899978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer.
    Kong FS; Li L; Wang W; Campbell J; Waller JL; Piert M; Gross M; Cheng M; Owen D; Stenmark M; Huang KC; Frey KA; Ten Haken RK; Lawrence TS
    Radiother Oncol; 2019 Mar; 132():241-249. PubMed ID: 30389239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
    Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
    Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary tumor standardized uptake value (SUVmax) measured on
    Hui Z; Wei F; Ren H; Xu W; Ren X
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2595-2605. PubMed ID: 32494919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
    Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of metabolic tumor volume of pretreatment
    Kumasaka S; Nakajima T; Arisaka Y; Tokue A; Achmad A; Fukushima Y; Shimizu K; Kaira K; Higuchi T; Tsushima Y
    BMC Med Imaging; 2018 Nov; 18(1):46. PubMed ID: 30477476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The correlation of
    Qu YH; Long N; Ran C; Sun J
    Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation study on 18F-FDG PET/CT metabolic characteristics of primary lesion with clinical stage in lung cancer.
    Hu WD; Wang HC; Wang YB; Cui LL; Chen XH
    Q J Nucl Med Mol Imaging; 2021 Jun; 65(2):172-177. PubMed ID: 30916535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Value of Metabolic and Volumetric Parameters of Preoperative FDG-PET/CT in Patients With Resectable Pancreatic Cancer.
    Im HJ; Oo S; Jung W; Jang JY; Kim SW; Cheon GJ; Kang KW; Chung JK; Kim EE; Lee DS
    Medicine (Baltimore); 2016 May; 95(19):e3686. PubMed ID: 27175707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.